As the Vice President of Therapeutic Research and External Innovation Lead at Entrada Therapeutics, I drive the development of novel clinical candidates, focusing on biologics and AONs to target rare neuromuscular and cardiac indications. Recently, I have successfully advanced several exon-skipping programs for Duchenne Muscular Dystrophy (DMD) through global regulatory filings.

With over twenty years of translational biology experience in rare and ultra-rare diseases, I began my professional career as a faculty member at Boston University, where I conducted research in regenerative biology and muscular dystrophy. In 2016, I transitioned to the biopharma sector, leading a neuromuscular group that supports both skeletal and cardiac muscle programs.